Researchers Develop mRNA Delivery System That Crosses Blood-Brain Barrier

A breakthrough using peptide-functionalized lipid nanoparticles could pave the way for targeted treatments of neurological diseases like Alzheimer's and Parkinson's.

Scientists have engineered lipid nanoparticles (LNPs) that can cross the blood-brain barrier and deliver mRNA to specific brain cells, such as neurons and endothelial cells.
The innovation uses peptides, which are smaller and more stable than antibodies, to guide the LNPs to their precise cellular targets within the brain.
This advancement holds potential for developing mRNA-based therapies for neurodegenerative diseases, avoiding invasive procedures like direct brain injections.
Researchers are now working to determine the fraction of neurons that must be treated to achieve meaningful therapeutic effects for neurological conditions.
The study represents a significant step forward in nonviral mRNA delivery for brain diseases, with future work aimed at refining efficiency and scaling clinical applications.